Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Kala Bio's share price for the quarter that ended in Mar. 2024 was $7.98069. Kala Bio's Shares Outstanding (EOP) for the quarter that ended in Mar. 2024 was 2.82 Mil. Therefore, Kala Bio's market cap for the quarter that ended in Mar. 2024 was $22.48 Mil.
Kala Bio's quarterly market cap
declined
from Sep. 2023 ($23.80 Mil) to Dec. 2023 ($19.27 Mil) but then
increased
from Dec. 2023 ($19.27 Mil) to Mar. 2024 ($22.48 Mil).
Kala Bio's annual market cap
declined
from Dec. 2021 ($78.73 Mil) to Dec. 2022 ($19.72 Mil) and
declined
from Dec. 2022 ($19.72 Mil) to Dec. 2023 ($19.27 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Kala Bio's Enterprise Value for Today is $6.42 Mil.
Kala Bio Market Cap Historical Data
The historical data trend for Kala Bio's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Kala Bio's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kala Bio's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kala Bio's Market Cap distribution charts can be found below:
* The bar in red indicates where Kala Bio's Market Cap falls into.
Kala Bio Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Kala Bio's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kala Bio (LTS:0JQ2) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Kala Bio Market Cap Related Terms
Thank you for viewing the detailed overview of Kala Bio's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing innovative therapies for rare and severe eye diseases. KALA's lead product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LTS:0JQ2 has been successfully added to your 